Kairos Pharma closed at $0.49 on Nov 4, down 3.03%, 95.8% below its 52-week closing high. Volume of 43.7K shares was 0.09× its 20-day average (below normal).
Split-adjusted performance: -57.4% over one month, -87.4% over six months, -93.1% over one year.
Short interest was 134.5K shares at the Oct 15 settlement, up 18.9% from the prior report (0.9% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KAPAKairos Pharma | $0.4897 | −3.03% | −87.4% | — | — | — | $1.7M | |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
| OGENOragenics | $0.3720 | +0.51% | −40.0% | — | — | — | $1.7M | Compare |
| GNPXGenprex | $2.14 | −7.36% | −89.1% | — | — | — | $1.8M | Compare |
| PPCBPropanc Biopharma | $1.79 | +4.68% | −92.9% | — | — | — | $1.8M | Compare |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| ARTLArtelo Biosciences | $2.27 | −5.42% | −90.9% | — | — | — | $1.2M | Compare |
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
